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Production of immunoreactive insulin-like growth factor-I (IGF-I) and
IGF-I binding proteins by human lung tumours
J.G. Reeve, J.A. Payne & N.M. Bleehen
Clinical Oncology and Radiotherapeutics Unit, MRC Centre, Hills Road, Cambridge CB2 2QH, UK.
Summary The production of insulin-like growth factor I (IGF-I) and IGF-I binding proteins (BPs) by human
lung tumour cell lines in vitro has been examined and the levels of these substances in the serum of lung cancer
patients investigated. While small cell lung cancer (SCLC) cell lines secreted both IGF-I and BPs, non-small
cell lung cancer (NSCLC) cell lines secreted BPs only. No evidence of increased serum IGF-I levels was
obtained in a cohort of 52 lung cancer patients having SCLC and NSCLC histologies. In contrast, serum
levels of low molecular weight BPs were markedly elevated in the majority of lung cancer patients.
The detection of elevated immunoreactive insulin-like growth
factor-I (IGF-I) in human lung tumours (Minuto et al., 1986;
Macaulay et al., 1988a) together with the observed secretion
of immunoreactive IGF-I by selected small cell lung cancer
(SCLC) cell lines in vitro (Jacques et al., 1988) raises the
possibility that IGF-I may be a clinically valuable serological
tumour marker in patients with lung tumours. However, in a
recent study of 42 untreated patients with histologically
confimed SCLC, evidence of elevated IGF-I levels was ob-
tained in two patients only (Macaulay et al., 1988b). The
present study was initiated to investigate further the secretion
of IGF-I by lung tumour cell lines in vitro and circulating
IGF-I levels in SCLC and non-small cell lung cancer
(NSCLC) patients. Since IGFs circulate in the blood com-
plexed to two different classes of binding protein (BP)
(Rinderknecht & Humbel, 1978; Smith, 1984) elimination of
BPs by effective extraction procedures is generally essential
for accurate quantification of IGF-I levels (Daughaday et al.,
1980; Baxter, 1986). BPs may lead to high values if the tracer
complexes to them, or may result in low values if ligand-BP
interaction is of high affinity, rendering bound ligand
unavailable for reaction with antibody. During the course of
this study it was noted that in contrast to unextracted sera
from healthy controls, unextracted sera from lung cancer
patients gave markedly higher IGF-I values, as determined
by radioimmunoassay, than extracted sera, perhaps suggest-
ing the presence of BPs in the lung cancer group. We here
report the production of both immunoreactive IGF-I and
BPs by lung tumour cells in vitro and the detection of
elevated serum levels of BPs but not IGF-I in SCLC and
NSCLC patients.
Materials and methods
Cell conditioned media
Full details of the derivation and characterisation of classic
SCLC cell lines COR-L51 and COR-L47, variant SCLC cell
lines COR-L24 and COR-L103, large cell lung cancer cell
line COR-L23 and B-lymphoblastoid lines COR-L26 and
COR-L65 have been previously described (Baillie-Johnson et
al., 1985). Classic SCLC cell line NCI-H69 (Gazdar et al.,
1986) was donated by Drs D. Carney and A. Gazdar (NCI
Navy Medical Oncology Branch, Bethesda, MD, USA). Cell
line MOR was derived from a patient having a lung
adenocarcinoma and was a gift from Dr M. Ellison (Ludwig
Institute, Sutton, UK).
For the production of conditioned media cells were grown
in serum free RPMI 1640 medium (Gibco Europe Ltd) for
72 h at a concentration of approximately 106 cells ml-'. Con-
ditioned media were harvested, clarified by centrifugation at
10,000g and stored at - 70'C in aliquots until use.
Serum samples
Serum was obtained from 52 newly diagnosed patients with
lung cancer. Thirty-five patients had histologically confirmed
SCLC, 11 had squamous cell carcinoma, 5 had large cell
carcinoma and 1 had adenocarcinoma.
Healthy adult male and female non-smokers (n = 32), and
male and female normal smokers (n = 31) were included in
the study as controls. The age range for controls was 23-81
years and for lung cancer patients 39-79 years.
Pre-treatment serum samples were prepared immediately
after collection and stored at - 70'C before assay.
IGF-I determinations
A radioimmunoassay (RIA) kit (Amersham International,
Aylesbury, UK) and a somatomedin C (SM-C) immuno-
radiometric (IRMA) kit (Immunodiagnostics Ltd, Tyne and
Wear, UK) were used for the quantitative measurement of
IGF-I in conditioned media and serum samples. Recom-
binant human IGF-I was used as standards in both assays.
The rabbit antiserum used in the competitive RIA was
raised against a recombinant analogue of IGF-I, shows
100% cross-reactivity with human IGF-I and 0.5% cross-
reactivity with human IGF-II. Fifty per cent displacement of
tracer occurs with insulin at 2,000ftunits ml-' (normal range
of insulin in fasting individuals is 4-30 gunits ml-' in
serum). Phase separation was achieved using Amerlex-M
donkey anti-rabbit reagent (Amersham UK). Assay sensi-
tivity is 100pg per tube.
The non-competitive SM-C IRMA employed a two site
immunoradiometric assay. Briefly standards/samples were
incubated simultaneously with a mouse monoclonal anti-SM-
C lgG immobilised on the inside walls of test tubes and a
'25I-labelled mouse monoclonal antibody directed against a
second IGF-I epitope. Unbound materials were then
removed by decanting and washing the tubes. The antisera
show 3% cross-reactivity with IGF-II and did not cross-react
at all with insulin or pro-insulin. The lowest detectable level
of SM-C that could be distinguished from the zero standard
was 8 mU ml' at the 95% confidence limit.
To separate binding protein from IGF-I, serum samples
and cell conditioned media were extracted by incubation in
50 of acid extraction solution (supplied by Immunodiag-
nostics Ltd) for 10min at room temperature. Neutralising
solution (500pl) (supplied by Immunodiagnostics Ltd) was
then added to each sample. This extraction procedure yields
aproximately 100% recovery of SM-C in patient samples.
The neutralised, extracted conditioned media and serum sam-
ples, and unextracted serum samples were then used in the
Amersham RIA and the IRMA.
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Detection ofIGF binding proteins by affinity labelling
Conditioned media or serum samples (10 1tI) diluted 1:10 in
0.5 M sodium phosphate buffer (pH 7.4) were pre-incubated
on ice for 30 min in the presence of approximately 250,000
c.p.m. of '251-IGF-I. Cross linking of '251-IGF-I to proteins
was accomplished by the addition of 51l of 20 mM disuc-
cinimidyl suberate (DSS) (Wilkins & D'Ercole, 1985) to give
a final concentration of 1 mM followed by incubation at
room temperature for Omin. To confirm the specificity of
the cross linking, the reaction was carried out in the presence
or absence of 500 ng of cold IGF-I. Samples were prepared
for electrophoresis by the addition of 0.0005% bromophenol
blue in 0.015 M Tris-HCI (pH 8.8). Electrophoresis was per-
formed on 7-15% linear gradient gels overnight at room
temperature with a constant current of 8 mA. Gels were fixed
in 3.5% acetic acid/10.5% methanol and autoradiographed.
Chromatography
Gel filtration chromatography was performed using a
2.5 x 1,000cm (bed volume = 465 ml) Sephacryl S 200 HR
(Pharmacia) column. Serum samples were eluted at 4°C in
0.1 M potassium phosphate buffer (pH 7.4) containing 0.15 M
NaCl and collected in 3 ml fractions which were monitored
for protein by determination of optical density at 280 nm.
Aliquots of fractions showing apparent immunoreactivity in
the Amersham RIA were affinity labelled with '251I-IGF-I in
the presence or absence of 500 ng IGF-I as described above.
Results
Detection ofimmunoreactive IGF-I in cell conditioned media
The concentrations of IGF-I in extracted conditioned media
as measured by the IDS IRMA are shown in Table I.
Immunoreactive IGF-I was detected in all media conditioned
by SCLC and B-lymphoblastoid cell lines. No IGF-I was
detectable in media conditioned by large cell lung cancer cell
line COR-L23 or by lung adenocarcinoma cell line MOR.
RPMI medium alone gave negative results.
Detection ofIGF-I binding proteins in cell-conditioned media
When SCLC and NSCLC lung tumour cell-conditioned
media were incubated with '25I-IGF-I and cross linked, a
number of specifically labelled IGF-I binding protein com-
plexes were detected (Figure 1). The most intensely labelled
complexes were of Mr 32 kDa and 37 kDa. Subtraction of
the molecular weight for IGF-I gives binding protein
molecular weights in the range of 25-30 kDa. More faintly
labelled binding proteins of Mr 16 kDa and 19 kDa were also
detected. No binding proteins were detected in media condi-
tioned by B-lymphoblastoid cell lines.
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Figure 1 Detection of IGF-I binding proteins in cell conditioned
media.
Comparison ofimmunoreactive IGF-I levels in acid extracted
and unextracted sera
It can be seen from Table II that acid extraction of control
and patient sera greatly improved the detection of IGF-I by
the IRMA method. The mean IGF-I level for lung cancer
patients is slightly lower than that for control subjects. Six
patients (12%) all with extensive disease, had levels at or
below the lower limit of normal, and there were no IGF-I
levels above the normal range.
The detection of IGF-I in control sera by RIA was not
significantly improved by acid extraction (Table II). The
mean serum IGF-I level in extracted sera from lung cancer
patients was again slightly lower than that for the control
group. However, it can be seen that in the Amersham RIA
unextracted sera from lung cancer patients gave markedly
higher IGF-I values than those for unextracted control sera.
Detection ofIGF-I and IGF-I binding proteins in Sephacryl
5200fractions ofserum
To determine whether the elevated values obtained in the
Amersham RIA for serum IGF-I concentrations in unex-
tracted cancer patient sera were due to binding protein
effects, cancer patient and normal serum was subjected to
neutral gel chromatography and the serum fractions screened
for reactivity in the Amersham RIA and IDS-IRMA assay.
Reactive fractions were then affinity labelled with '251-IGF-I
as described in Materials and methods, subjected to SDS gel
electrophoresis and autoradiographed.
For control sera, IGF-I immunoreactivity was detected by
both IDS-IRMA and Amersham RIA in fractions containing
proteins slightly smaller than the y-globulin peak (apparent
Mr of 150 kDa). A second smaller peak of reactivity eluted
from the column just after the albumin peak (apparent Mr of
50 kDa) (Figure 2a).
Table I Detection of IGF-I immunoreactivity in cell conditioned
media
IGF-I (mUml-')
Cell line Type ± s.e.m.a
COR-L51 Classic SCLC 16±2
COR-L47 Classic SCLC 16± I
COR-L27 Variant SCLC 15±2
COR-L24 Variant SCLC 16±2
COR-L103 Variant SCLC 22 ± I
COR-L23 Large cell n.d.
MOR Adenocarcinoma n.d.
COR-L65 B-Lymphoblastoid 22± 3
COR-L26 B-lymphoblastoid 20± 2
aResults are the means ± s.e.m. of four measurements; n.d. = not
detected.
Table II Comparison of immunoreactive IGF-I levels in acid
extracted and unextracted sera as detennined by RIA and IRMA
methods
RIA (Amersham) IRMA (IDS)
IGF (ngml ))a IGF (Uml-))b
Mean ± s.e.m. Mean ± s.e.m.
Extracted Unextracted Extracted Unextracted
Lung cancer 139.8 ± 9.8 354.1 ± 26.6 0.76± 0.12 0.32 ± 0.06
patients
Controls 162.8 ± 7.8 169.4 ± 9.0 1.06 ± 0.15 0.42 ± 0.04
aNormal range 86.8- 187 ng ml' (Furlanetto & Marino, 1987);
bNormal levels cited by manufacturer: 0.60-2.1 Uml-'.IGF-I AND BINDING PROTEINS IN LUNG TUMOURS 729
IRMA analysis of fractions from SCLC patient sera gave
similar results to those for normal serum with IGF-I eluting
in two peaks just after the y-globulin and albumin peaks. The
amounts of IGF-I in the two peaks from SCLC patient sera
were not significantly different from those in the peaks from
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normal sera. When fractions from SCLC patient sera were
screened with the Amersham RIA the first IGF-I peak de-
scribed above for normal sera was detected. In addition,
however, a major reactive peak co-eluting with the second
smaller IGF-I peak detected in normal sera, was also present
(Figure 2b).
Affinity labelling of SCLC serum fractions from this
second peak with '251 -IGF-I revealed the presence of
specifically labelled IGF-I binding protein complexes having
molecular weights ranging from 32 to 37 kDa (Figure 2b).
Although these complexes were detected in equivalent frac-
tions from normal sera (Figure 2a), labelling intensity was
greatly increased in fractions from SCLC sera.
Affinity-labelked IGE-I binding protein complexes in whole
serum
Representative autoradiographs of the specifically labelled
IGF-I BPs found in the sera of most SCLC and NSCLC
patients, and in most healthy controls are shown in Figure 3.
Serum IGF-I BP complexes with M, 32-37 kDa were much
more intensely labelled in most lung cancer patients com-
pared to those in most healthy controls (Figure 3, Table III).
Increased BP labelling was observed in SCLC patients with
limited and extensive disease and NSCLC patients with
squamous and large-cell carcinomas. Intensely labelled com-
plexes comparable to those seen in some lung cancer patients
were observed in a few healthy smokers (Table Ill).
Discussion
The present study has demonstrated the secretion of both
immunoreactive IGF-I and IGF-I BPs by SCLC cell lines in
vitro. Although NSCLC cell lines also secrete BPs, evidence
of IGF-I secretion was not obtained in this investigation.
Conversely B-lymphoblastoid cell lines secreted IGF-I but
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Figure 3 Representative autoradiographs of the specifically
labelled IGF-I binding protein complexes found in most lung
cancer patients, and most healthy controls.
Figure 2 Sephacryl S200 HR fractionation of unextracted sera
from a normal healthy individual (a) and from a SCLC patient
(b). The protein profiles, as measured by optical density at
280 nm, are displayed. Arrows indicate fractions in which peak
IGF-I immunoreactivity was detected by IDS-IRMA and Amer-
sham RIA. The larger arrow (b) also indicates the position of the
major reactive peak fraction in the Amersham RIA. Electro-
phoretic analysis and autoradiography of the IGF binding pro-
teins are shown as insets above the protein profiles.
Table III Frequency of increased labelling of binding proteins in
lung cancer patients and controls
No. with binding
No. studied protein abnormality
SCLC patients 22 20
NSCLC patients 5 5
Smoking controls 18 3
Non-smoking controls 15 0730 J.G. REEVE et al.
not BPs. These findings indicate that the synthesis of IGF-I
and BPs may occur independently in some tumour cell lines
in vitro but that in SCLC cells IGF-I synthesis is consistently
associated with that of BPs.
The observations that SCLC cell lines release IGF-I, ex-
press IGF-I receptors and respond mitogenically to IGF-I
(Jacques et al., 1988) suggest that IGF-I may be an autocrine
growth factor for SCLC tumours. Interestingly, several lines
of evidence suggest that BPs are involved in the modulation
of IGF-I mediated mitogenesis. BPs have been shown to
inhibit the effects of IGF-I and IGF-II on fibroblast DNA
synthesis (Knauer & Smith, 1980). Binding of these proteins
to cell surfaces increases the binding of IGF-I to its receptor
(Clemmons et al., 1986) and IGF-I BPs have been shown
markedly to potentiate the replication of human mouse and
chicken embryo fibroblasts in response to IGF-I stimulation
(Elgin et al., 1987). Hence the production of IGF-I BPs by
SCLC cells raises the possibility that these proteins similarly
modulate the mitogenic responsiveness of SCLC to IGF-I
stimulation. Studies are currently in progress to investigate
this possibility.
The present study also shows that although significant
amounts of IGF-I are produced by SCLC cells in vitro,
serum IGF-I levels are not raised in lung cancer patients
compared to normal controls. The apparently elevated levels
of IGF-I in the unextracted sera of cancer patients were
clearly due to BP effects as evidenced by the detection of
IGF-I binding proteins in cancer patient serum fractions
having reactivity in the Amersham RIA and by the results
obtained for extracted sera. The observation that serum
levels of IGF-I are not increased in SCLC patients, though
consistent with those of earlier reports (Minuto et al., 1986;
Macaulay et al., 1988b), is perhaps surprising given the
over-production of BPs in lung cancer patients and the
ability of BPs to prolong the half life of IGFs in the circula-
tion (Cohen & Nissley, 1976; Zapf et al., 1979). One explana-
tion is that the release of IGF-I from SCLC cells in vivo is,
like IGF-I release from liver, hormonally regulated by
mechanisms which do not exist in vitro. Alternatively, if
IGF-I is indeed an autocrine growth factor for SCLC cells,
secreted IGF-I may rapidly associate with IGF-I receptors
and may be subsequently internalised and degraded.
Significant changes in serum levels of the autocrine growth
factor gastrin releasing peptide are similarly only rarely seen
(Pert & Schumacher, 1982).
In contrast to IGF-I, serum levels of low molecular weight
BPs were markedly elevated in SCLC and NSCLC patients
compared to normal healthy non-smokers and most healthy
smokers. Although affinity labelling does not yield an
autoradiographic signal proportional to the amount of pro-
tein present and is affected by binding site occupancy, the
observed production of BPs by lung tumour cells in vitro
supports the contention that there is a quantitative increase
in circulating BPs in lung cancer patients. The frequency with
which BP abnormalities were detected in lung cancer patients
raises the possibility that IGF-I BPs may be clinically useful
tumour markers for both SCLC and NSCLC tumours.
Indeed our preliminary studies indicate that BP levels reflect
tumour burden and may also be of value in disease monitor-
ing.
The lung tumour derived 25-30 kDa BPs produced by
lung tumour cell lines in vitro and also detected in the serum
of lung cancer patients are also present in the serum of
normal healthy individuals. Hence they are likely to belong
to the family of small molecular weight BPs which are
growth hormone independent (Hardouin et al., 1987; Hintz
et al., 1981; Hall et al., 1988). Proteins of this group have
been termed placental protein 12 (ppl2) (Koishnen et al.,
1986), BP28 (Baxter et al., 1987), IGFBP-25 (Lee et al.,
1988), IBP-1 (Brinkman et al., 1988) and pregnancy
associated endometrial-y-globulin (Bell & Keyte, 1988).
Amino acid sequence analyses indicate that many of the
smaller molecular weight BPs characterised to date are, in
fact, a single protein encoded by the IBP-1 gene (Lee et al.,
1988; Brinkman et al., 1988; Baxter & Martin, 1989).
Recently, however, a novel human binding protein IGFBP-2
has been identified with a predicted molecular weight of
31 kDa (Binkert et al., 1989) which has a higher affinity for
IGF-II than IGF-I and which is encoded by the IGFBP-2
gene. Studies are in progress to investigate the relationship
between lung tumour IGF-BPs and the different low
molecular weight IBP-1 and IGFBP-2 BPs.
Serum concentration of the smaller molecular weight BP is
influenced by a variety of physiological factors (Baxter &
Martin, 1989). In normal subjects the levels of BP fall from
birth to adulthood, increase during pregnancy, show diurnal
rhythmicity, vary inversely with growth hormone status and
increase with hypoglycaemia. Increased serum levels have
been observed in trophoblastic disease, pre-eclampsia and
ovarian cancer (Baxter & Martin, 1989). In the present study
blood samples were taken from patients and controls at
approximately equivalent times, there were no cases of preg-
nancy in either group and no evidence of hypoglycaemia in
cancer patients when pre-treatment blood samples were
taken. Hence it is unlikely that the elevated levels of BPs
detected in cancer patient sera compared to normal controls
are due to factors which normally influence BP serum
concentration. The observation that serum levels of
the low molecular weight BPs are apparently increased in
some healthy smokers is of interest and under further inves-
tigation.
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